ISCO
Price
$0.15
Change
-$0.00 (-0.00%)
Updated
Aug 14 closing price
Capitalization
1.2M
LIXT
Price
$3.59
Change
-$0.31 (-7.95%)
Updated
Aug 15 closing price
Capitalization
16.38M
Interact to see
Advertisement

ISCO vs LIXT

Header iconISCO vs LIXT Comparison
Open Charts ISCO vs LIXTBanner chart's image
International Stem Cell
Price$0.15
Change-$0.00 (-0.00%)
Volume$386
Capitalization1.2M
Lixte Biotechnology Holdings
Price$3.59
Change-$0.31 (-7.95%)
Volume$100.97K
Capitalization16.38M
ISCO vs LIXT Comparison Chart in %
Loading...
ISCO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LIXT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ISCO vs. LIXT commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ISCO is a Hold and LIXT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (ISCO: $0.15 vs. LIXT: $3.59)
Brand notoriety: ISCO and LIXT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ISCO: 6% vs. LIXT: 4%
Market capitalization -- ISCO: $1.2M vs. LIXT: $16.38M
ISCO [@Biotechnology] is valued at $1.2M. LIXT’s [@Biotechnology] market capitalization is $16.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ISCO’s FA Score shows that 1 FA rating(s) are green whileLIXT’s FA Score has 0 green FA rating(s).

  • ISCO’s FA Score: 1 green, 4 red.
  • LIXT’s FA Score: 0 green, 5 red.
According to our system of comparison, ISCO is a better buy in the long-term than LIXT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ISCO’s TA Score shows that 3 TA indicator(s) are bullish while LIXT’s TA Score has 4 bullish TA indicator(s).

  • ISCO’s TA Score: 3 bullish, 5 bearish.
  • LIXT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, LIXT is a better buy in the short-term than ISCO.

Price Growth

ISCO (@Biotechnology) experienced а +20.30% price change this week, while LIXT (@Biotechnology) price change was -25.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LIXT($16.4M) has a higher market cap than ISCO($1.21M). ISCO YTD gains are higher at: 85.117 vs. LIXT (76.873). ISCO has higher annual earnings (EBITDA): 111K vs. LIXT (-3.31M). ISCO (1.45M) and LIXT (1.39M) have equal amount of cash in the bank . LIXT has less debt than ISCO: LIXT (100K) vs ISCO (4.1M). ISCO has higher revenues than LIXT: ISCO (9.09M) vs LIXT (0).
ISCOLIXTISCO / LIXT
Capitalization1.21M16.4M7%
EBITDA111K-3.31M-3%
Gain YTD85.11776.873111%
P/E RatioN/AN/A-
Revenue9.09M0-
Total Cash1.45M1.39M105%
Total Debt4.1M100K4,095%
FUNDAMENTALS RATINGS
ISCO vs LIXT: Fundamental Ratings
ISCO
LIXT
OUTLOOK RATING
1..100
5096
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
77
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3935
P/E GROWTH RATING
1..100
89100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ISCO's Valuation (5) in the null industry is significantly better than the same rating for LIXT (77). This means that ISCO’s stock grew significantly faster than LIXT’s over the last 12 months.

ISCO's Profit vs Risk Rating (100) in the null industry is in the same range as LIXT (100). This means that ISCO’s stock grew similarly to LIXT’s over the last 12 months.

ISCO's SMR Rating (100) in the null industry is in the same range as LIXT (100). This means that ISCO’s stock grew similarly to LIXT’s over the last 12 months.

LIXT's Price Growth Rating (35) in the null industry is in the same range as ISCO (39). This means that LIXT’s stock grew similarly to ISCO’s over the last 12 months.

ISCO's P/E Growth Rating (89) in the null industry is in the same range as LIXT (100). This means that ISCO’s stock grew similarly to LIXT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ISCOLIXT
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 6 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
ISCO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LIXT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STKH0.86N/A
+0.01%
Steakholder Foods Ltd
PNW91.34-0.57
-0.62%
Pinnacle West Capital Corp
LTBR16.17-0.13
-0.80%
Lightbridge Corp
ATKR57.86-1.33
-2.25%
Atkore
GCTS1.26-0.08
-5.97%
GCT Semiconductor Holding

ISCO and

Correlation & Price change

A.I.dvisor tells us that ISCO and HNSBF have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ISCO and HNSBF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ISCO
1D Price
Change %
ISCO100%
N/A
HNSBF - ISCO
22%
Poorly correlated
N/A
CRDF - ISCO
20%
Poorly correlated
N/A
LIXT - ISCO
7%
Poorly correlated
-7.95%
INTI - ISCO
7%
Poorly correlated
+2.30%
INRLF - ISCO
5%
Poorly correlated
N/A
More

LIXT and

Correlation & Price change

A.I.dvisor indicates that over the last year, LIXT has been loosely correlated with PTHS. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if LIXT jumps, then PTHS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LIXT
1D Price
Change %
LIXT100%
-7.95%
PTHS - LIXT
34%
Loosely correlated
+10.55%
NTLA - LIXT
28%
Poorly correlated
+0.83%
IBIO - LIXT
28%
Poorly correlated
+9.32%
BBIO - LIXT
27%
Poorly correlated
+0.27%
PMN - LIXT
26%
Poorly correlated
-2.06%
More